Docoh
Loading...

BCLI Brainstorm Cell Therapeutics

News

From Benzinga Pro
BrainStorm Cell ALS Candidate Shows Benefit In Patients With Less Severe Disease
29 Nov 21
Biotech, News, Penny Stocks, Health Care, General
BrainStorm Cell Therapeutics Announces The Presentation Of New Analyses From The Phase 3 Trial Of NurOwn In ALS At The 4th Annual ALS ONE Research Symposium
29 Nov 21
News, Events
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the Phase 3 trial of NurOwn at the 4th
68 Biggest Movers From Wednesday
26 Nov 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) shares gained 689.4% to settle at $78.94 on Wednesday after the company priced its IPO at $10 per share.
BCLI: Biomarkers Predict Response in ALS Phase 3 Trial…
17 Nov 21
Penny Stocks
By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT
Brainstorm Cell Q3 EPS $(0.15) Beats $(0.20) Estimate
15 Nov 21
Earnings, News
Brainstorm Cell (NASDAQ:BCLI) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.20) by 25 percent. This is a 7.14 percent decrease over losses of $(0.14) per share from the
Earnings Scheduled For November 15, 2021
15 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its third quarter.
BrainStorm Announces Scientific Presentation Of NurOwn Exosome Preclinical ARDS Data At NYSCF 2021 VIRTUAL Meeting
18 Oct 21
News, Events
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "Therapeutic Benefits of MSC-NTF
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021
6 Oct 21
Biotech, News, Events, General
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF biomarker correlations with primary
BrainStorm Cell Therapeutics To Present Phase 2 Data Results At Congress of the European Committee for Treatment and Research in Multiple Sclerosis Oct. 14 At 10:45 a.m. EDT
1 Oct 21
News, Events
BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and Efficacy Study
TENX: Second Quarter Results
20 Sep 21
Penny Stocks
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

Press releases

From Benzinga Pro
BrainStorm Cell Therapeutics to Present New Biomarker Data on NurOwn® at the International Symposium on ALS/MND
2 Dec 21
Press Releases
NEW YORK, Dec. 2, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced that biomarker data on NurOwn® will
BrainStorm Cell Therapeutics Announces the Presentation of New Analyses from the Phase 3 Trial of NurOwn® in ALS at the 4th Annual ALS ONE Research Symposium
29 Nov 21
Press Releases
NEW YORK, Nov. 29, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the presentation of new analyses from the
BrainStorm Cell Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
15 Nov 21
Earnings, Press Releases
NEW YORK, Nov. 15, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced financial results for the quarter ended
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
8 Nov 21
Press Releases
NEW YORK, Nov. 8, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced executive appointments as the company
MOV.AI appoints Liat Soffer as CFO to support scaling its business
8 Nov 21
Fintech, Press Releases
TEL AVIV, Israel and LISBON, Portugal, Nov. 8, 2021 /PRNewswire/ -- MOV.AI, developer of the revolutionary Robotics Engine PlatformTM, today announced the recent addition of Liat Soffer to its management team, as Chief
Brainstorm Cell Therapeutics Announces Appointment of Menghis Bairu, MD, to Board of Directors
28 Oct 21
Press Releases
NEW YORK, Oct. 28, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the appointment of Menghis Bairu, MD, to
BrainStorm to Announce Third Quarter Financial Results and Provide a Corporate Update
25 Oct 21
Press Releases
NEW YORK, Oct. 25, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting
18 Oct 21
Small Cap, Press Releases
NEW YORK, Oct. 18, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled,
Phase 2 Clinical Trial Data of NurOwn® in Progressive MS Will Be Presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
14 Oct 21
Press Releases
NEW YORK, Oct. 14, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, will present findings from a multicenter, open label
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting October 6th, 2021
6 Oct 21
Press Releases
NEW YORK, Oct. 6, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "CSF
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa
4 Oct 21
Press Releases
NEW YORK, Oct. 4, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that Stacy Lindborg, Ph.D., Executive Vice
BrainStorm to Present Phase 2 Progressive MS Study Results in Oral Presentation at 37th Congress of ECTRIMS
1 Oct 21
Press Releases
NEW YORK, Oct. 1, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled